You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Express Scripts
Colorcon
Mallinckrodt

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OCRELIZUMAB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ocrelizumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00077870 A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis Completed Genentech, Inc. Phase 1/Phase 2 2004-02-01 This is a randomized, placebo-controlled, multicenter, blinded Phase I/II, investigator and subject-blinded study of the safety of escalating doses of ocrelizumab in combination with MTX in subjects with moderate to severe RA
NCT00406419 A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE) Terminated Roche Pharma AG Phase 3 2006-12-01 This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.
NCT00406419 A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE) Terminated Genentech, Inc. Phase 3 2006-12-01 This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.
NCT00476996 A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) Active, not recruiting Roche Pharma AG Phase 3 2007-05-01 This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment will be administered at weeks 24 and 26. All patients will receive stable doses of either concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive additional DMARDs. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ocrelizumab

Condition Name

Condition Name for ocrelizumab
Intervention Trials
Multiple Sclerosis 13
Rheumatoid Arthritis 8
Multiple Sclerosis, Relapsing-Remitting 5
Relapsing Multiple Sclerosis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ocrelizumab
Intervention Trials
Multiple Sclerosis 31
Sclerosis 28
Multiple Sclerosis, Relapsing-Remitting 8
Multiple Sclerosis, Chronic Progressive 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ocrelizumab

Trials by Country

Trials by Country for ocrelizumab
Location Trials
United States 373
Italy 87
Canada 52
Spain 45
Brazil 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ocrelizumab
Location Trials
California 19
Ohio 18
New York 18
Texas 17
Tennessee 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ocrelizumab

Clinical Trial Phase

Clinical Trial Phase for ocrelizumab
Clinical Trial Phase Trials
Phase 4 8
Phase 3 25
Phase 2 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ocrelizumab
Clinical Trial Phase Trials
Not yet recruiting 16
Recruiting 10
Active, not recruiting 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ocrelizumab

Sponsor Name

Sponsor Name for ocrelizumab
Sponsor Trials
Genentech, Inc. 20
Hoffmann-La Roche 16
Roche Pharma AG 8
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ocrelizumab
Sponsor Trials
Industry 45
Other 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
McKesson
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.